SEC Form 4 · accession 0001104659-26-082010
Cellectar Biosciences, Inc. · CLRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Neis
Director
Period of report
Jul 7, 2026
Accepted (ET)
Jul 8, 2026 · 9:02 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001279704
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $2.70 | Jul 7, 2026 | A | 25,000 | A | — | Jul 7, 2036 | Common stock | 25,000 | 25,000 | D |
Explanation of responses
- F1This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.